放疗联合或不联合顺铂治疗子宫内膜癌局部复发:NRG Oncology/GOG前瞻性随机多中心临床试验结果
该随机多中心试验纳入165例子宫内膜癌局部复发患者,1:1随机接受单纯放疗或放化疗。单纯放疗组中位无进展生存期未达到,放化疗组为73个月,风险比为1.25(95%CI 0.75-2.07);3年无进展生存率分别为73%和62%。放化疗未改善无进展生存期且急性毒性更高,多数低级别阴道复发患者最适合单纯放疗。
要点
- 子宫内膜癌局部复发患者单纯放疗即可获得良好结局
- 加用顺铂化疗未改善无进展生存期且增加急性毒性
- 低级别阴道复发患者最适合单纯放疗
核心结论
- 子宫内膜癌局部复发患者接受根治性放疗可获得良好结局,加用化疗未改善无进展生存期且增加急性毒性,多数入组的低级别阴道复发患者最适合单纯放疗。
研究设计与样本
- 2008年2月至2020年8月开展的前瞻性随机多中心临床试验,165例患者按1:1随机分配接受单纯放疗或放化疗,主要目的为确定放化疗是否比单纯放疗更有效改善无进展生存期。
主要发现
- 多数患者为低级别(1或2级)子宫内膜样组织学(82%),复发局限于阴道(86%)。
- 单纯放疗组中位无进展生存期未达到,放化疗组为73个月,风险比为1.25(95%CI 0.75-2.07)。
- 3年时,单纯根治性放疗组73%的患者存活且无疾病进展,放化疗组为62%。
- 放化疗组急性毒性发生率高于单纯放疗组。
关键数值与推荐
- 随机分配接受化疗的患者接受每周一次顺铂(40 mg/m2)治疗。
- 体外照射采用三维或调强放疗技术,后续通过近距离放疗或体外照射进行推量。
临床怎么用
- 对于子宫内膜癌局部复发患者,根治性放疗可获得良好结局。
- 加用化疗未改善无进展生存期且增加急性毒性。
- 低级别和阴道复发的患者(占入组大多数)最适合单纯放疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pelvic recurrence is a frequent pattern of relapse for women with endometrial cancer. A randomized trial compared progression-free survival (PFS) after treatment with radiation therapy alone as compared with concurrent chemotherapy. MATERIALS AND METHODS: Between February 2008 and August 2020, 165 patients were randomly assigned 1:1 to receive either radiation treatment alone or a combination of chemotherapy and radiation treatment. The primary objective of this study was to determine whether chemoradiation therapy was more effective than radiation therapy alone at improving PFS. RESULTS: The majority of patients had low-grade (1 or 2) endometrioid histology (82%) and recurrences confined to the vagina (86%). External beam with either the three-dimensional or intensity modulated radiation treatment technique was followed by a boost delivered with brachytherapy or external beam. Patients randomly assigned to receive chemotherapy were treated with once weekly cisplatin (40 mg/m2). Rates of acute toxicity were higher in patients treated with chemoradiation as compared with radiation treatment alone. Median PFS was longer for patients treated with radiation therapy alone as compared with chemotherapy and radiation (median PFS was not reached for RT v 73 months for chemoradiation, hazard ratio of 1.25 (95% CI, 0.75 to 2.07). At 3 years, 73% of patients treated definitively with radiation and 62% of patients treated with chemoradiation were alive and free of disease progression. CONCLUSION: Excellent outcomes can be achieved for women with localized recurrences of endometrial cancer when treated with radiation therapy. The addition of chemotherapy does not improve PFS for patients treated with definitive radiation therapy for recurrent endometrial cancer and increases acute toxicity. Patients with low-grade and vaginal recurrences who constituted the majority of those enrolled are best treated with radiation therapy alone.
引用
- Klopp AH, Enserro D, Powell M, et al. Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial. J Clin Oncol. 2024. PMID: 38662968. doi:10.1200/JCO.23.01279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。